Education and Training
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: BMS-986288
- drug: Nivolumab
- drug: Regorafenib
Eligibility
Inclusion Criteria:
- Histologic or cytologic confirmation of select solid tumor that is advanced
(metastatic, recurrent, and/or unresectable) with measurable disease and have at least
1 lesion accessible for biopsy
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Received, and then progressed, relapsed, or been intolerant to, at least 1 standard
treatment regimen in the advanced or metastatic setting according to select solid
tumor histologies
Exclusion Criteria:
- Active, known or suspected autoimmune disease
- Active malignancy requiring concurrent intervention
- Primary Central Nervous System (CNS) malignancies or tumors with CNS metastasis as the
only site of disease, will be excluded
Other protocol-defined inclusion/exclusion criteria apply
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Flordeliza Mendoza
650-724-2056
Not Recruiting